Clinical trials: Antiretroviral Therapy
Hiv, Cardiovascular Diseases
The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy
Introduction An increase in cardiovascular disease (CVD) among people living with HIV infection is linked to platelet and immune activation, a phenomenon unabolished by antiretroviral (ARV) drugs alone.
- Trial name
- NCT05525156
- Testing
- aspirin enteric coated tablet 75 mg
- Where
- Tanzania
- Volunteers
- 454 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Central Nervous System Lymphoma, AIDS Related Lymphoma
Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy
This study aims at describing survival rates over time (Kaplan-Meier estimator) in patients suffering from AIDS-related primary central nervous system lymphoma who were diagnosed from 1996 to 2014 and treated with infusions of…
- Trial name
- LCPVIH (NCT03690895)
- Testing
- Retrospective survival analysis
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Human Immunodeficiency Virus (HIV)
An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate
The purpose of this study is to describe the effectiveness of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF), measured as virological response at Week 48 as per Food and Drug Administration (FDA) snapshot…
- Trial name
- DIAMANTE (NCT03577470)
- Testing
- D/C/F/TAF Fixed-Dose Combination (FDC)
- Where
- 18 sites in Italy
- Volunteers
- 246 people
- Sponsor
- Janssen-Cilag S.p.A.
HIV Infections
Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection
The purpose of this study is to evaluate the safety of the experimental drug Bay 50-4798 in HIV positive patients receiving HAART and to test the drug's effect on the CD4+ T-cell count.
- Trial name
- NCT00059462
- Testing
- Interleukin-2 SA, HAART
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 56 people
- Sponsor
- Bayer
HIV Infection, Tuberculosis
Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment
This study investigates the prevention of early mortality in patients initiating antiretroviral therapy (ART) in sub-Saharan Africa where 79% of the co-infected cases of TB reside.
- Trial name
- PrOMPT (NCT01417988)
- Testing
- Experimental: Empiric TB treatment, ART only arm
- Where
- 3 sites in Gabon, Mozambique and 1 more
- Volunteers
- 44 people
- Sponsor
- Prof JMA Lange
HIV-1 Infection
Lipopeptide Immunisation With GTU-multiHIV Trial
The combination of GTU-MultiHIV B DNA and LIPO-5 vaccines in a prime-boost strategy is expected to induce strong and diverse HIV-specific immune responses in HIV-infected patients.
- Trial name
- NCT01492985
- Testing
- GTU-multHIV B vaccine and LIPO-5 vaccine
- Where
- France
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously
This is an open label study (no placebos are used; all patients will receive the true medication) to evaluate the effectiveness of TMC114/rtv in treatment naÃ-ve (never previously received anti-HIV drugs), HIV 1 infected patients.
- Trial name
- NCT00513513
- Testing
- TMC114 (darunavir) / ritonavir
- Volunteers
- 7 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
The Safety and Effectiveness of Two Forms of Saquinavir Combined With Other Anti-HIV Drugs in HIV-Infected Infants and Children
To determine the pharmacokinetic properties, tolerance and safety of 2 formulations of saquinavir, given in combination with 2 nucleoside antiretroviral drugs (part 1) or in combination with nelfinavir and nucleoside…
- Trial name
- NCT00002380
- Testing
- Nelfinavir mesylate, Saquinavir
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Hoffmann-La Roche
Primary Biliary Cholangitis
Combination Antiretroviral Therapy (cART) for PBC
Placebo Controlled, double-blind randomized controlled trial (RCT) with 12 months Tenofovir Disoproxil and Raltegravir for primary biliary cholangitis (PBC) patients unresponsive to Ursodeoxycholic Acid (UDCA).
- Trial name
- NCT03954327
- Testing
- Emtricitabine (FTC)/Tenofovir Disoproxil (TDF), Raltegravir
- Where
- 6 sites in Canada
- Volunteers
- 37 people
- Sponsor
- University of Alberta
HIV Infections, Acquired Immunodeficiency Syndrome
Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285
This is an international study of vicriviroc in 500 adult HIV-infected subjects who are failing standard antiretroviral therapy (ART). HIV must be of a certain type known as R5/X4-mixed tropic.
- Trial name
- NCT00243568
- Testing
- Vicriviroc
- Sponsor
- Merck Sharp & Dohme LLC
HIV-infected Patients
Values of the Immune Activation Markers CD38 and HLA-DR and the Ratio CD4/CD8 According to the Delay of Combined AntiRetroviral Therapy (c-ART) Initiation in Primary HIV-infected Patients (PRIMIMMUNO)
The objective was to identify factors associated with the normalization of the CD4/CD8 ratio (>=1) in patients with a history of primary HIV infection (PHI) and long-term combined antiretroviral therapy (cART).
- Trial name
- PRIMIMMUNO (NCT02827227)
- Testing
- lymphocytes immunophenotyping
- Where
- France
- Volunteers
- 99 people
- Sponsor
- Hospices Civils de Lyon
HIV Infections
Duration of Dual Antiretroviral Therapy in Virologically Suppressed People Living With HIV and Factors Associated With Switching to Tritherapy : a Real-life Cohort
HIV infection requires lifelong continuous antiretroviral (ARV) treatment. The efficacy of current ARV treatments makes it possible to propose strategies for reducing the cumulative exposure to ARVs, side effects and costs.
- Trial name
- TOBIT (NCT06107140)
- Testing
- dual therapy
- Where
- France
- Volunteers
- 580 people
- Sponsor
- Tourcoing Hospital
HIV Infections
A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs
To make stavudine (d4T) available to patients with advanced HIV disease for whom no alternative antiretroviral is satisfactory. To study the safety and efficacy of two dose levels in a twice-daily regimen.
- Trial name
- NCT00002308
- Testing
- Stavudine
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Pharmacokinetics of Raltegravir During Third Trimester Pregnancy and Post-Partum
This study will evaluate the pharmacokinetic disposition of raltegravir in pregnant HIV-1 infected women. These results will be compared to pharmacokinetic data obtained following pregnancy as well as to studies previously…
- Trial name
- NCT00689910
- Where
- 4 sites in United States
- Sponsor
- University of California, San Francisco
Hypercholesterolemia, Inflammation
NUtraceutical TReatment for hYpercholesterolemia in HIV-infected Patients
The effects of a nutraceutical combination (NC) containing low-dose monacolin K and berberine on lipid profile, proprotein convertase subtilisin/kexin type 9 (PCSK9), subclinical inflammation and arterial stiffness were…
- Conditions
- Hypercholesterolemia, Inflammation, Atherosclerosis
- Trial name
- NU-TRY(HIV) (NCT03470376)
- Testing
- Nutraceutical combination (NC), No nutraceutical combination (noNC)
- Volunteers
- 26 people
- Sponsor
- University Of Perugia
HIV
The Safety and Immunogenicity of the DNA-GTU Vaccine Administered to HIV-infected Patients on ART vs Placebo
CUT*HIVTHER 001 is a randomised placebo-controlled Phase I/II study aimed at exploring the safety and immunogenicity of two different modes of delivery of a GTU® DNA plasmid vaccine (GTU®-multiHIV B clade) in HIV infected…
- Trial name
- CUTHIVTHER001 (NCT02457689)
- Testing
- GTU®-MultiHIV B Clade Vaccine, Sodium chloride BP
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Imperial College London
Liver Fibrosis, Steatohepatitis
Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy
This study will provide a basis for research on the impact of liver injury caused by antiretroviral therapy in HIV-infected patients.
- Conditions
- Liver Fibrosis, Steatohepatitis, Elevated Transaminases
- Trial name
- NCT00326482
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Women's Health, HIV Infection
Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract
Increases in cluster of differentiation 4 (CD4)+ T cells in the blood is well documented in human immunodeficiency virus (HIV)-infected individuals after starting antiretroviral therapy (ART), but increases CD4+ T cells in the…
- Conditions
- Women's Health, HIV Infection, Genital Diseases, Female
- Trial name
- NCT01456962
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Colorado, Denver
Antiretroviral Treatment, HIV Infection
Incidence of Metabolic Syndrome in People Living With HIV Without ExperienCe to ART Who Start DoLutegravir Based-Regimen Compared With BictegrAvir Based-RegimeN
The aim of the study was to identify the incidence of MetS at 48 weeks for ATP III score in patients living with HIV (PLH) who started antiretroviral therapy (ART) with Dolutegravir based-regimen compared with Bictegravir…
- Conditions
- Antiretroviral Treatment, HIV Infection, Metabolic Cardiovascular Syndrome
- Trial name
- MICTLAN (NCT06629480)
- Testing
- Bictegravir
- Where
- Mexico
- Volunteers
- 378 people
- Sponsor
- Instituto Mexicano del Seguro Social
AIDS/HIV PROBLEM
Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection
This study is to evaluate the safety and efficacy of RAL-based regimen in treatment-experienced patients with resistant HIV infection
- Trial name
- NCT01844310
- Testing
- RAL+TDF+LPV/r, 3TC+TDF+LPV/r
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.